RxDoctor Payments Data

Anna Park, MD

Ophthalmology · Silver Spring, MDNPI 1295730521

Payments from drug & device makers

$1,431in general payments, 2019–2025

Across 38 payments — averaging $37.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$335
  • AbbVie$214
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$134
  • Shire North American Group Inc$123
  • Aerie Pharmaceuticals, Inc.$116
  • Tarsus Pharmaceuticals, Inc.$112
  • plus $396 from 9 others

What the payments were for

  • Food & beverage$1,431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,431 in reported general payments places this provider in the 50th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$116,551
Medicare patients
411
Services billed
1,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine19$28,419
Timolol Maleate56$3,950
SimbrinzaBrinzolamide/Brimonidine Tart11$2,980
Latanoprost152$2,064
Brimonidine Tartrate25$1,966
Prednisolone Acetate17$582
Dorzolamide Hcl24$557
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat32$458
ErythromycinErythromycin Base23$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$214$28,41919 claims
AlconSimbrinza$68$2,98011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →